, Volume 15, Issue 4, pp 239–249 | Cite as

Comparative Efficacy of Inhaled Corticosteroids and Antileukotriene Drugs in Asthma

Review Article


Asthma is an inflammatory disease of the airways that is best treated by minimising exposure to factors that provoke the inflammation (e.g. allergens) and by administering drugs that reduce the inflammatory response. The cornerstone of asthma treatment is inhaled corticosteroids. Their effectiveness is a result of their potent and broad anti-inflammatory properties. Antileukotriene drugs (leukotriene modifiers) provide an alternative and novel approach to the treatment of asthma. The novelty of these new compounds is that their effectiveness is firmly based on the pathophysiology of asthma, specifically the role played by the cysteinyl leukotrienes. At the same time, the availability of the antileukotriene drugs has stirred debate over when they should be used and how they compare to inhaled corticosteroids. Although the answers are not fully known at this time, the currently available published and presented data are adequate for us to draw some conclusions about their relative effectiveness and role in asthma treatment. The antileukotriene drugs are more effective than placebo, but they are not as effective as inhaled corticosteroids in improving lung function [measured as the forced expiratory volume in 1 second (FEV1) or peak expiratory flow rate (PEFR)], reducing β2-agonist use, and decreasing symptom-free days. In contrast, they may have similar beneficial effects on reducing asthma exacerbations and decreasing peripheral blood eosinophil counts. In the absence of knowing a priori the response of an individual patient to treatment with either therapy, the data favour initiating treatment with an inhaled corticosteroid. However, for patients with mild to moderate disease there are a number of circumstances that support using an antileukotriene drug first. A few examples are aspirin intolerance, predominantly exercise-induced symptoms and problems with using an inhaler or the adverse effects of inhaled corticosteroids such as dysphonia and thrush. For patients with more severe disease, inhaled corticosteroids remain the treatment of choice. Antileukotriene drugs should be considered as add-on therapy, especially in view of their possible complementary effects on reducing airway inflammation.


  1. 1.
    Guidelines for the diagnosis and management of asthma. Expert Panel Report II. NIH publication no. 97-4051. Bethesda (MD): National Institutes of Health, 1997Google Scholar
  2. 2.
    Holgate S. Mediator and cytokine mechanisms in asthma. Thorax 1993; 48: 103–9PubMedCrossRefGoogle Scholar
  3. 3.
    Lee TH. Cytokine networks in the pathogenesis of bronchial asthma: implications for therapy. J R Coll Phys Lond 1998; 32: 56–64Google Scholar
  4. 4.
    Smith LJ. Leukotrienes in asthma. Arch Intern Med 1996; 156: 2181–9PubMedCrossRefGoogle Scholar
  5. 5.
    Smith LJ. A risk-benefit assessment of antileukotrienes in asthma. Drug Saf 1998; 19: 205–18PubMedCrossRefGoogle Scholar
  6. 6.
    Drazen JM, Israel E, O’Byrne PM. Treatment of asthma with drugs modifying the leukotriene pathway. N Engl J Med 1999; 340: 197–206PubMedCrossRefGoogle Scholar
  7. 7.
    Barnes PJ, Pedersen S, Busse WW. Efficacy and safety of inhaled corticosteroids. Am J Respir Crit Care Med 1998; 157: S1–53PubMedGoogle Scholar
  8. 8.
    Malmstrom K, Rodriguez-Gomez G, Guerra J, et al. Oral montelukast, inhaled beclomethasone, and placebo for chronic asthma. Ann Intern Med 1999; 130: 487–95PubMedGoogle Scholar
  9. 9.
    Booth H, Richmond I, Ward C, et al. Effect of high dose inhaled fluticasone propionate on airway inflammation in asthma. Am J Respir Crit Care Med 1995; 152: 45–52PubMedGoogle Scholar
  10. 10.
    Sont JK, Han J, van Krieken JM, et al. Relationship between the inflammatory infiltrate in bronchial biopsy specimens and clinical severity of asthma in patients treated with inhaled corticosteroids. Thorax 1996; 51: 496–502PubMedCrossRefGoogle Scholar
  11. 11.
    Wenzel SE, Szefler SJ, Leung DYM, et al. Bronchoscopic evaluation of severe asthma. Persistent inflammation associated with high dose glucocorticoids. Am J Respir Crit Care Med 1997; 156: 737–43PubMedGoogle Scholar
  12. 12.
    Chung KF. Corticosteroid responsiveness and the evolution of asthma. Clin Exp Allergy 1998; 28Suppl. 5: 126–32PubMedCrossRefGoogle Scholar
  13. 13.
    Manso G, Baker AJ, Taylor IK, et al. In vivo and in vitro effects of glucocorticoids on arachidonic acid metabolism and monocyte function in nonasthmatic tissue. Eur Respir J 1992; 5: 712–6PubMedGoogle Scholar
  14. 14.
    Cowburn AS, Holgate ST, Sampson AP. IL-5 increases expression of 5-lipoxygenase activating protein and translocates 5-lipoxygenase to the nucleus in human blood eosinophils. J Immunol 1999; 163: 456–65PubMedGoogle Scholar
  15. 15.
    Riddick CA, Ring WL, Baker JR, et al. Dexamethasone increases expression of 5-lipoxygenase and its activating protein in human monocytes and THP-1 cells. Eur J Biochem 1997; 246: 112–8PubMedCrossRefGoogle Scholar
  16. 16.
    Pouliot M, McDonald PP, Borgeat P, et al. Granulocyte/macrophage colony-stimulating factor stimulates the expression of the 5-lipoxygenase-activating protein (FLAP) in human neutrophils. J Exp Med 1994; 179: 1225–32PubMedCrossRefGoogle Scholar
  17. 17.
    Dworski R, Fitzgerald GA, Oates JA, et al. Effect of oral prednisone on airway inflammatory mediators in atopic asthma. Am J Respir Crit Care Med 1994; 149: 953–9PubMedGoogle Scholar
  18. 18.
    O’Shaughnessy KM, Wellings R, Gillies B, et al. Differential effects of fluticasone propionate on allergen-evoked bronchoconstriction and increased urinary leukotriene E4 excretion. Am Rev Respir Dis 1993; 147: 1472–6PubMedGoogle Scholar
  19. 19.
    Smith LJ, Hanby LA, Lavins BJ, et al. A single dose of zafirlukast reduces LTD4-induced bronchoconstriction in patients on maintenance inhaled corticosteroid therapy. Ann Asthma Allergy Immunol 1998; 81: 43–9CrossRefGoogle Scholar
  20. 20.
    Reiss TF, Sorkness CA, Stricker W, et al. Effect of montelukast, a potent cysteinyl leukotriene receptor antagonist, on bronchodilation in asthmatic subjects treated with and without inhaled corticosteroids. Thorax 1997; 52: 45–8PubMedCrossRefGoogle Scholar
  21. 21.
    Tamaoki J, Kondo M, Sakai N, et al. Leukotriene antagonist prevents exacerbation of asthma during reduction of highdose inhaled corticosteroid. Am J Respir Crit Care Med 1997; 155: 1235–40PubMedGoogle Scholar
  22. 22.
    Lofdahl C-G, Reiss TF, Leff JA, et al. Randomized, placebo controlled trial of effect of a leukotriene receptor antagonist, montelukast, on tapering inhaled corticosteroids in asthmatic patients. BMJ 1999; 319: 87–90PubMedCrossRefGoogle Scholar
  23. 23.
    Laviolette M, Malmstrom K, Lu S, et al. Montelukast added to inhaled beclomethasone in treatment of asthma. Am J Respir Crit Care Med 1999; 160: 1862–8PubMedGoogle Scholar
  24. 24.
    Virchow IC, Prasse A, Naya I, et al. Zafirlukast improves asthma control in patients receiving high-dose inhaled corticosteroids. Am J Respir Crit Care Med 2000; 162: 578–85PubMedGoogle Scholar
  25. 25.
    Reiss TF, Chervinsky P, Dockhorn RJ, et al. Montelukast, a once-daily leukotriene receptor antagonist, in the treatment of chronic asthma: a multicenter, randomized, double-blind trial. Arch Intern Med 1998; 158: 1213–20PubMedCrossRefGoogle Scholar
  26. 26.
    Calhoun WJ, Lavins BJ, Minkwitz MC, et al. Effect of zafirlukast (Accolate) on cellular mediators of inflammation: bronchoalveolar lavage fluid findings after segmental antigen challenge. Am J Respir Crit Care Med 1998; 157: 1381–9PubMedGoogle Scholar
  27. 27.
    Pizzichini E, Leff JA, Reiss TF, et al. Montelukast reduces airway eosinophilic inflammation in asthma: a randomized, controlled trial. Eur Respir J 1999; 14: 12–8PubMedCrossRefGoogle Scholar
  28. 28.
    Drazen JM, Israel E. Should antileukotriene therapies be used instead of inhaled corticosteroids in asthma? Yes. Am J Respir Crit Care Med 1998; 158: 1697–8Google Scholar
  29. 29.
    Wenzel SE. Should antileukotriene therapies be used instead of inhaled corticosteroids in asthma? No. Am J Respir Crit Care Med 1998; 158: 1699–701Google Scholar
  30. 30.
    Smith LJ. Newer asthma therapies. Ann Intern Med 1999; 130: 531–2PubMedGoogle Scholar
  31. 31.
    Bleecker E, Welch MJ, Weinstein SF, et al. Low-dose inhaled fluticasone propionate versus oral zafirlukast in the treatment of persistent asthma. J Allergy Clin Immunol 2000; 105: 1123–9PubMedCrossRefGoogle Scholar
  32. 32.
    Laitinen LA, Naya IP, Binks S, et al. Comparative efficacy of zafirlukast and low dose steroids in asthmatics on prn β2-agonists [abstract]. Eur Respir J 1997; 10: 419sGoogle Scholar
  33. 33.
    Busse W, Srebro SH, Edwards L, et al. Low dose inhaled fluticasone propionate versus oral zafirlukast in asthma patients [abstract]. Am J Respir Crit Care Med 1999; 159: A628Google Scholar
  34. 34.
    Skalky CS, Edelman JM, Polis A, et al. Montelukast sodium compared to inhaled beclomethasone dipropionate in adult asthmatics: a randomized clinical trial [abstract]. J Allergy Clin Immunol 1999; 103: S228Google Scholar
  35. 35.
    Busse W, Raphael GD, Galant S, et al. Low-dose fluticasone propionate compared with montelukast for first-line treatment of persistent asthma: a randomized clinical trial. J Allergy Clin Immunol 2001; 107: 461–8PubMedCrossRefGoogle Scholar
  36. 36.
    Spector SL, Smith LJ, Glass M, and the Asthma Accolate Trialists Group. Effects of 6 weeks therapy with oral doses of ICI 204,219, a leukotriene D4 receptor antagonist, in subjects with bronchial asthma. Am J Respir Crit Care Med 1994; 150: 618–23PubMedGoogle Scholar
  37. 37.
    Liu MC, Dube LM, Lancaster J, et al. Acute and chronic effects of a 5-lipoxygenase inhibitor in asthma: a 6-month randomized multicenter trial. J Allergy Clin Immunol 1996; 98: 859–71PubMedCrossRefGoogle Scholar
  38. 38.
    Israel E, Cohn J, Dube L, et al. Effect of treatment with zileuton, a 5-lipoxygenase inhibitor, in patients with asthma. JAMA 1996; 275: 931–6PubMedCrossRefGoogle Scholar
  39. 39.
    Israel E, Rubin P, Kemp JP, et al. The effect of inhibition of 5-lipoxygenase by zileuton in mild-to-moderate asthma. Ann Intern Med 1993; 119: 1059–66PubMedGoogle Scholar
  40. 40.
    Fish JE, Kemp JP, Lockey RF, et al. Zafirlukast improves symptomatic mild to moderate asthma: a 13-week multicenter study. Clin Ther 1997; 19: 675–90PubMedCrossRefGoogle Scholar
  41. 41.
    Reiss TF, Altman LC, Chervinsky P, et al. Effect of montelukast (MK-0476), a new potent cysteinyl leukotriene (LTD4) receptor antagonist, in patients with chronic asthma. J Allergy Clin Immunol 1996; 98: 528–34PubMedCrossRefGoogle Scholar
  42. 42.
    Kemp J, Wanderer AA, Ramsdell J, et al. Rapid onset of control with budesonide Turbuhaler in patients with mild-to-moderate asthma. Ann Allergy Asthma Immunol 1999; 82: 463–71PubMedCrossRefGoogle Scholar
  43. 43.
    Sheffer AL, LaForce C, Chervinsky P, et al. Fluticasone propionate aerosol: efficacy in patients with mild to moderate asthma. J Fam Pract 1996; 42: 369–75PubMedGoogle Scholar
  44. 44.
    Nathan RA, Nolop KB, Cuss FM, et al. A comparison of double-strength beclomethasone dipropionate (84 mcg) with beclomethasone dipropionate (42 mcg) MDI in the treatment of asthma. Chest 1997; 112: 34–9PubMedCrossRefGoogle Scholar
  45. 45.
    Pauwels RA, Lofdahl CG, Postma DS, et al. Effect of inhaled formoterol and budesonide on exacerbations of asthma. N Engl J Med 1997; 337: 1405–1PubMedCrossRefGoogle Scholar
  46. 46.
    Evans DJ, Taylor DA, Zetterstrom O, et al. A comparison of low-dose inhaled budesonide plus theophylline and highdose inhaled budesonide for moderate asthma. N Engl J Med 1997; 337: 1412–8PubMedCrossRefGoogle Scholar
  47. 47.
    Israel E, Fischer AR, Rosenberg MA, et al. The pivotal role of 5-lipoxygenase products in the reaction of aspirin-sensitive asthmatics to aspirin. Am Rev Respir Dis 1993; 148: 1447–51PubMedCrossRefGoogle Scholar
  48. 48.
    Cowburn AS, Sladek, K, Soja J, et al. Overexpression of leukotriene C4 synthase in bronchial biopsies from patients with aspirin-intolerant asthma. J Clin Invest 1998; 101: 834–46PubMedCrossRefGoogle Scholar
  49. 49.
    Hasday JD, Meltzer SS, Moore WC, et al. Anti-inflammatory effects of zileuton in a subpopulation of allergic asthmatics. Am J Respir Crit Care Med 2000; 161: 1229–36PubMedGoogle Scholar
  50. 50.
    Drazen JM, Yandava CN, Dube L, et al. Pharmacogenetic association between ALOX5 promoter genotype and the response to anti-asthma treatment. Nature Genetics 1999; 22: 168–70PubMedCrossRefGoogle Scholar
  51. 51.
    Anderson W, Kalberg C, Edwards L, et al. Effects of polymorphisms in promoter region of 5-lipoxygenase and LTC4 synthase on the clinical response to zafirlukast and fluticasone [abstract]. Eur Respir J 2000; 16Suppl. 31: 183sGoogle Scholar

Copyright information

© Adis International Limited 2001

Authors and Affiliations

  1. 1.Office of Clinical Research and Training, Division of Pulmonary and Critical Care Medicine and the Department of Veterans Affairs, Chicago Healthcare System, Lakeside DivisionNorthwestern UniversityChicagoUSA

Personalised recommendations